VentriPoint Diagnostics (CVE:VPT) Reaches New 1-Year High – Should You Buy?

VentriPoint Diagnostics Ltd. (CVE:VPT)’s stock price hit a new 52-week high during trading on Friday . The company traded as high as C$0.19 and last traded at C$0.17, with a volume of 719109 shares. The stock had previously closed at C$0.14.

VentriPoint Diagnostics Stock Up 22.2%

The stock’s fifty day moving average price is C$0.11 and its 200 day moving average price is C$0.11. The stock has a market cap of C$30.96 million, a P/E ratio of -5.50 and a beta of -1.00. The company has a current ratio of 0.05, a quick ratio of 6.67 and a debt-to-equity ratio of -50.43.

VentriPoint Diagnostics Company Profile

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients.